Duramed/Schein conjugated estrogens settlement
Executive Summary
Schein has given up claims to any rights over Duramed's Cenestin (conjugated estrogens A) product. Duramed has paid Schein $7.5 mil. as part of the settlement, and an additional $7.5 mil. in cash or stock is due Jan. 20. If Cenestin sales exceed $100 mil. over any five year period in the next 15 years, Schein is entitled to another $15 mil